ASPHF (Ascentage Pharma Group International) PB Ratio: 8.99 (As of Jun. 25, 2026) — 23% Below Median


ASPHF Ascentage Pharma Group International ASPHF
71 GF Score
Price $4.53
GF Value $6.61
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International PB Ratio?

Ascentage Pharma Group International ASPHF -3.51% 71 PB Ratio is 8.99 as of Jun. 25, 2026, which is 23% below its 10-year median of 11.62. GuruFocus rates ASPHF with a GF Score™ of 71/100 and a GF Value™ of $6.61 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,233 Biotechnology companies, Ascentage Pharma Group International ranks worse than 82% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Ascentage Pharma Group International's share price is $4.53. Ascentage Pharma Group International's Book Value per Share for the quarter that ended in Dec. 2025 was $0.50. Hence, Ascentage Pharma Group International's PB Ratio of today is 8.99.

Good Sign:

Ascentage Pharma Group International stock PB Ratio (=7.96) is close to 3-year low of 7.96.

The historical rank and industry rank for Ascentage Pharma Group International's PB Ratio or its related term are showing as below:

ASPHF' s PB Ratio Range Over the Past 10 Years
Min: 1.99   Med: 11.62   Max: 209.21
Current: 7.96

During the past 10 years, Ascentage Pharma Group International's highest PB Ratio was 209.21. The lowest was 1.99. And the median was 11.62.

ASPHF's PB Ratio is ranked worse than
82% of 1233 companies
in the Biotechnology industry
Industry Median: 2.8 vs ASPHF: 7.96

During the past 12 months, Ascentage Pharma Group International's average Book Value Per Share Growth Rate was 337.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 31.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -21.00% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Ascentage Pharma Group International was 31.60% per year. The lowest was -62.80% per year. And the median was -37.45% per year.

Back to Basics: PB Ratio


Ascentage Pharma Group International  (OTCPK:ASPHF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Ascentage Pharma Group International PB Ratio Related Terms


Ascentage Pharma Group International PB Ratio Historical Data

* Premium members only.

The historical data trend for Ascentage Pharma Group International's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International PB Ratio Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.28 15.38 110.69 23.39 16.83

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.69 8.01 23.39 21.90 16.83

ASPHF vs VRTX, REGN, ALNY: PB Ratio Comparison

For the Biotechnology subindustry, Ascentage Pharma Group International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's PB Ratio falls into.


ASPHF
71GF Score
Ascentage Pharma Group International ASPHF
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascentage Pharma Group International PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Ascentage Pharma Group International's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=4.53/0.504
=8.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 8.99 mean?
Ascentage Pharma Group International (ASPHF) has a PB Ratio of 8.99 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ascentage Pharma Group International and its competitors. This is 23% below median its historical median of 11.62. Over the past decade, Ascentage Pharma Group International's PB Ratio has ranged from 1.99 to 209.21. According to the industry distribution chart, Ascentage Pharma Group International ranks #1011 out of 1233 companies in the Biotechnology industry, placing it in the top 82%.
Is Ascentage Pharma Group International's PB Ratio too high?
Ascentage Pharma Group International's current PB Ratio of 8.99 is 23% below median its 10-year median of 11.62. Over the past 10 years, this metric has ranged from a low of 1.99 to a high of 209.21. The Biotechnology industry median PB Ratio is 2.80. Ascentage Pharma Group International's value of 8.99 is 221.1% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #1011 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #1011 out of 1233 companies for PB Ratio. This places Ascentage Pharma Group International in the lower half of its industry. The industry median PB Ratio is 2.80. Ascentage Pharma Group International's value of 8.99 is 221.1% above this benchmark. Historically, Ascentage Pharma Group International's own PB Ratio has ranged from 1.99 to 209.21 over the past decade. While the company's 10-year median is 11.62 vs. the industry median of 2.80, Ascentage Pharma Group International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current PB Ratio of 8.99 is 221.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current PB Ratio is 8.99, which is 23% below median its own 10-year median of 11.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current PB Ratio is 8.99, which is 23% below median its 10-year median of 11.62 and 221.1% above the Biotechnology industry median of 2.80. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current PB Ratio is 8.99 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

  • PB Ratio: 8.99 (23% below median its 10-year median of 11.62)
  • GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
  • GF Score™: 71/100 with 7 warning signs
  • Industry Position: 221.1% above the Biotechnology median (#1011 of 1233)

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score

Get the complete analysis for ASPHF

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$6.61
GF Value